Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of "Hold" from Brokerages

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) has been given an average recommendation of "Hold" by the twenty-five research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $80.20.

Several equities research analysts have weighed in on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Piper Sandler raised their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Evercore ISI decreased their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,012 shares of company stock worth $4,224,717. 1.29% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the business. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $26,000. SouthState Corp bought a new position in Edwards Lifesciences in the 1st quarter worth approximately $27,000. Finally, Rossby Financial LCC bought a new position in Edwards Lifesciences in the 1st quarter worth approximately $29,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.3%

Shares of NYSE:EW opened at $77.56 on Friday. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $95.25. The stock has a market cap of $45.50 billion, a P/E ratio of 11.13, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business's 50 day moving average is $73.98 and its 200 day moving average is $72.77. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.66 EPS. Sell-side analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.